Pulse Biosciences is a bioelectric medicine company focused on health innovation using its patented Nano-Pulse Stimulation (NPS) technology, an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as a Nanosecond Pulsed-Field Ablation (nsPFA) technology when used to ablate cellular tissue. The CellFX System is a software-enabled, console-based platform, designed to accommodate the clinical workflow preferred by physicians. The CellFX System is configured to accept a variety of handpieces or electrodes. The PLSE stock yearly return is shown above.
The yearly return on the PLSE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PLSE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|